Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit
TAMPA, FLORIDA & STOCKHOLM, SWEDEN – March 15, 2019 – Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned ...
Read More
Read More
Cell & Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa
Vycellix is advancing pipeline of modulators and next-generation T cell & NK cell therapies for treatment of cancers Company to present on Cell Therapy Manufacturing Panel ...
Read More
Read More
Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer
Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 ...
Read More
Read More
Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit
New Products Enhance Genetic Modification of Lymphocytes and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company ...
Read More
Read More